| Xu, Binghe |
TROPHY, NCT06245824: Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial |
|
|
| Not yet recruiting | 4 | 51 | RoW | Trastuzumab deruxtecan (T-DXd) with pyrotinib, (T-DXd) with pyrotinib | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Breast Cancer | 03/26 | 12/26 | | |
NCT05291910: Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer |
|
|
| Not yet recruiting | 4 | 70 | RoW | Inetetamab, Toripalimab, Albumin-Bound Paclitaxel | Chinese Academy of Medical Sciences | Breast Cancer | 12/24 | 12/25 | | |
NCT02595138: Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer |
|
|
| Active, not recruiting | 3 | 430 | RoW | Zoledronic acid | Chinese Academy of Medical Sciences, Beijing Municipal Science & Technology Commission | Triple Negative Breast Cancer | 10/18 | 12/23 | | |
TQB2450-III-06, NCT04405505: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) |
|
|
| Not yet recruiting | 3 | 332 | RoW | TQB2450, Anlotinib, Paclitaxel for Injection (albumin bound) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Triple Negative Breast Cancer | 07/22 | 07/22 | | |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
NCT04851613: Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer |
|
|
| Recruiting | 3 | 256 | US, RoW | Afuresertib, Fulvestrant, Afuresertib/placebo | Laekna Limited | Breast Cancer | 10/26 | 12/26 | | |
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
| Completed | 3 | 275 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 12/22 | 03/24 | | |
NCT03876886: The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency |
|
|
| Recruiting | 3 | 200 | RoW | Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin | Chinese Academy of Medical Sciences | Triple Negative Breast Cancer | 02/24 | 12/24 | | |
NCT06343948: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer |
|
|
| Recruiting | 3 | 382 | RoW | BL-B01D1, Eribulin, Vinorelbine, Gemcitabine, Capecitabine | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | HR+HER2- Breast Cancer | 05/26 | 05/26 | | |
BRIGHT-2, NCT05077449: A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 300 | RoW | XZP-3287+Fulvestrant, Placebo + Fulvestrant | Xuanzhu Biopharmaceutical Co., Ltd. | Advanced Breast Cancer | 02/24 | 11/29 | | |
NCT05439499: This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. |
|
|
| Recruiting | 3 | 434 | RoW | FCN-437c, Letrozole or anastrozole, Goserelin acetate, Placebo, Letrozole or anastrozole, Goserelin acetate | Ahon Pharmaceutical Co., Ltd. | Advanced Breast Cancer, Female Breast Cancer | 09/24 | 03/25 | | |
AK112-308, NCT06767527: AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer |
|
|
| Not yet recruiting | 3 | 416 | RoW | AK112, Nab-paclitaxel, Placebo | Akeso | Triple-Negative Breast Cancer (TNBC) | 12/26 | 12/28 | | |
| Recruiting | 3 | 530 | RoW | SHR-A1811, Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel | Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 01/25 | 06/26 | | |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
| Recruiting | 3 | 376 | RoW | SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Metastatic Breast Cancer | 03/26 | 12/27 | | |
TQB3616-III-03, NCT05780567: Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer |
|
|
| Recruiting | 3 | 1946 | RoW | TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen, Placebo capsules, Letrozole, Anastrozole, Tamoxifen | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Breast Cancer | 12/26 | 01/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Active, not recruiting | 2/3 | 549 | Europe, RoW | Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol® | Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd. | Recurrent or Metastatic Breast Cancer | 02/24 | 12/25 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
EVER-132-001, NCT04454437: Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments |
|
|
| Active, not recruiting | 2 | 80 | RoW | Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132 | Gilead Sciences, IQVIA RDS (Shanghai) Co., Ltd., Medidata Solutions, Q Squared Solutions (Beijing) Co., Ltd, Parexel | Metastatic Triple-negative Breast Cancer | 08/21 | 12/25 | | |
|
NCT04452370: Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer |
|
|
| Recruiting | 2 | 100 | RoW | oral etoposide + anlotinib, there is no other intervention name | Chinese Academy of Medical Sciences | Triple Negative Breast Cancer | 07/22 | 07/23 | | |
NCT05747326: Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer |
|
|
| Recruiting | 2 | 30 | RoW | oral vinorelbine and capecitabine, metronomic agents (vinorelbine and capecitabine ) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Breast Cancer | 06/23 | 06/23 | | |
NCT05749016: Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer |
|
|
| Recruiting | 2 | 30 | RoW | inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen, Cipterbin with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Locally Advanced Breast Cancer, Chemotherapy Effect | 07/23 | 12/23 | | |
NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 133 | RoW | TJ107 +Pembrolizumab | TJ Biopharma Co., Ltd. | Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma | 06/24 | 12/24 | | |
TSL-CM-TSL1502-Ⅱ, NCT05420779: A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations |
|
|
| Recruiting | 2 | 125 | RoW | TSL-1502 capsules(low dose), TSL-1502 capsules(high dose), Investigator's choice of chemotherapy | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. | Breast Cancer Metastatic | 12/24 | 06/26 | | |
NCT06810804: A Phase IIa Study to Evaluate the Efficacy and Safety of NBQ72S |
|
|
| Not yet recruiting | 2 | 10 | NA | NBQ72S, QBS10072S | Nantong Bencao Quadriga Medical Technology Co. Ltd. | Breast Cancer | 08/26 | 02/27 | | |
NCT04539496: A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 402 | RoW | XZP-3287, XZP-3287;Letrozole;Anastrozole;Fulvestrant | Sihuan Pharmaceutical Holdings Group Ltd. | Metastasis Solid Tumors, Advanced Breast Cancer | 07/23 | 12/25 | | |
NCT05747313: Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer |
|
|
| Recruiting | 1/2 | 40 | RoW | Chidamide, Epidaza | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Breast Cancer, Chemotherapy Effect | 06/23 | 12/23 | | |
NCT03125746: A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 72 | RoW | LXI-15029, LXI-15029+Exemestane | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Advanced Breast Cancer | 10/21 | 10/21 | | |
NCT04433494: A Study of TY-302 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 60 | RoW | TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg, TY-302, Tamoxifen Citrate | TYK Medicines, Inc | Breast Cancer, Solid Tumor | 05/23 | 12/23 | | |
| Active, not recruiting | 1 | 297 | RoW | FS-1502 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Solid Tumor, Breast Cancer | 04/24 | 06/25 | | |
NCT05341570: A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668 |
|
|
| Recruiting | 1 | 60 | RoW | BPI-21668 | Betta Pharmaceuticals Co., Ltd. | Advanced Solid Tumor | 01/24 | 01/25 | | |
NCT05700084: Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 84 | RoW | Utidelone Capsule (Part 1), Drug A Utidelone Capsule (Part 2: Group A-B), Drug A Utidelone Capsule (Part 2: Group B-A), Drug B Utidelone Injection (Part 2: Group A-B), Drug B Utidelone Injection (Part 2: Group B-A), Capecitabine, Utidelone Capsule (Part 3) | Beijing Biostar Pharmaceuticals Co., Ltd. | Advanced Solid Tumor | 03/25 | 04/25 | | |
NCT05390710: PhI to Solid Tumors and PhII to Locally Advanced or mTNBC |
|
|
| Completed | 1 | 21 | RoW | LAE005 + Afuresertib + Nab-Paclitaxel | Laekna Limited | Solid Tumor, TNBC - Triple-Negative Breast Cancer | 12/23 | 12/23 | | |
NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors |
|
|
| Recruiting | 1 | 150 | RoW | SPH5030 tablets | Shanghai Pharmaceuticals Holding Co., Ltd | HER2-positive Advanced Solid Tumors | 12/24 | 12/24 | | |
NCT05628870: A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer |
|
|
| Recruiting | 1 | 102 | RoW | HRS-1358 | Shandong Suncadia Medicine Co., Ltd. | Breast Cancer | 12/24 | 06/25 | | |
NCT06609187: A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | GNC-077 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer, Solid Tumor | 10/26 | 10/26 | | |
NCT06614751: A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway |
|
|
| Not yet recruiting | 1 | 112 | RoW | DAT-2645 tablet | Danatlas Pharmaceuticals Co., Ltd | Solid Cancers, BRCA Mutation, HRD Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, Endometrial Cancer, Gastric Cancer, Advanced Cancer, Metastatic Solid Tumors | 11/26 | 06/27 | | |
NCT06770569: Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors |
|
|
| Not yet recruiting | 1 | 100 | RoW | HRS-3802 | Shandong Suncadia Medicine Co., Ltd. | Advanced Solid Tumors | 12/28 | 12/28 | | |
NCT05673694: To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer. |
|
|
| Recruiting | 1 | 70 | RoW | EG017 | Changchun GeneScience Pharmaceutical Co., Ltd. | Breast Cancer | 11/25 | 01/26 | | |
NCT05728541: Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors |
|
|
| Not yet recruiting | 1 | 367 | RoW | SYH2043 | CSPC Ouyi Pharmaceutical Co., Ltd. | Advanced Malignant Tumors | 02/26 | 03/26 | | |
NCT05895825: A Study of EOC237 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 48 | RoW | EOC237 | Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd | Advanced Solid Tumor | 04/26 | 09/26 | | |
NCT06156761: Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer |
|
|
| Not yet recruiting | N/A | 24 | RoW | Mitoxantrone hydrochloride liposome, Capecitabine | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, CSPC Ouyi Pharmaceutical Co., Ltd. | Breast Cancer | 04/24 | 04/25 | | |
| Poosarla, Teja |
NCT05812807: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab |
|
|
| Recruiting | 3 | 1295 | Canada, US | Pembrolizumab, Keytruda, Patient Observation, Active surveillance, watchful waiting, observation, Biopsy, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma | 05/33 | 05/33 | | |
NCT05616624: ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers |
|
|
| Recruiting | 1/2 | 114 | US | ADI-PEG 20, PEGylated arginine deiminase, Gemcitabine, Gemzar, Docetaxel, Taxotere | Washington University School of Medicine, Polaris Group | Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Small Cell Lung Carcinoma | 12/27 | 12/32 | | |
| Alkharabsheh, Omar |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
| Completed | 2 | 131 | Canada, US | brentuximab vedotin, Adcetris; SGN-35, bendamustine, dacarbazine, nivolumab | Seagen Inc., Bristol-Myers Squibb | Hodgkin Disease, Peripheral T Cell Lymphoma | 04/23 | 09/23 | | |
|
|
|
|
|
| Rodgers, Lisa |
TRACC, NCT04050345: Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer |
|
|
| Recruiting | N/A | 1000 | Europe | | Royal Marsden NHS Foundation Trust | Colorectal Cancer | 07/29 | 07/31 | | |
